QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for securities fraud violations.

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against uniQure N.V. (NASDAQ: QURE) for violations of securities laws. Investors who purchased the company's securities between September 24, 2025, and October 31, 2025, are encouraged to contact the firm before April 13, 2026 to participate in the lawsuit.

Why it matters

This lawsuit alleges that uniQure made false and misleading statements to the market about its ability to secure full FDA approval for its Pivotal Study, misleading investors about the company's timeline for its Biologics License Application (BLA) submission.

The details

According to the complaint, uniQure failed to secure full FDA approval for its Pivotal Study and misled the market about its ability to delay the BLA timeline to supplement the data submitted to the FDA. The company's public statements were allegedly false and materially misleading throughout the class period, resulting in investor losses when the truth came to light.

  • The class period is from September 24, 2025, to October 31, 2025, inclusive.
  • The deadline to contact the Schall Law Firm to participate in the lawsuit is April 13, 2026.

The players

uniQure N.V.

A biopharmaceutical company focused on the development of gene therapies for rare and other devastating diseases.

Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm (Business Wire)

What’s next

The judge in the case will decide on whether to certify the class by April 13, 2026.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures by public companies, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the biopharmaceutical industry and the regulatory oversight of clinical trial data and regulatory submissions.